10 drug(s) with this reaction
3,496 total reports
Product Use In Unapproved Indication has been reported as an adverse reaction across 10 drug(s) manufactured by Chattem Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 3,496 adverse event reports mention product use in unapproved indication in connection with Chattem Inc products.
This page provides a breakdown of which Chattem Inc drugs are most commonly associated with product use in unapproved indication, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Chattem Inc drugs have product use in unapproved indication listed in their FDA adverse event reports, sorted by report count:
In addition to product use in unapproved indication, the following adverse reactions have been reported across Chattem Inc's drug portfolio:
10 drug(s) manufactured by Chattem Inc have product use in unapproved indication listed in their FDA adverse event reports: TRIAMCINOLONE ACETONIDE, LIDOCAINE, MENTHOL, LEVOCETIRIZINE DIHYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE, MENTHOL, and others.
There are a combined 3,496 reports of product use in unapproved indication across 10 Chattem Inc drug(s) in the FDA adverse event database.